Cas No.: | 2361659-61-0 |
Chemical Name: | Chembl4520400 |
Synonyms: | 4-(N-(4-(tert-butyl)benzyl)-2-((4-fluoro-N-((perfluorophenyl)methyl)phenyl)sulfonamido)acetamido)-N-hydroxybenzamide;BDBM50519452;Chembl4520400;AES-135 |
SMILES: | S(C1C([H])=C([H])C(=C([H])C=1[H])F)(N(C([H])([H])C1C(=C(C(=C(C=1F)F)F)F)F)C([H])([H])C(N(C1C([H])=C([H])C(C(N([H])O[H])=O)=C([H])C=1[H])C([H])([H])C1C([H])=C([H])C(=C([H])C=1[H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])=O)(=O)=O |
Formula: | C33H29F6N3O5S |
M.Wt: | 693.6559 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | AES-135 (AES135) is a novel HDAC inhibitor that biochemically inhibits HDACs 3, 6, 8 and 11 with IC50 values of 190-1100 nM; exhibits selective in vitro cytotoxicity in low passage patient-derived pancreatic cancer cells even in the presence of cancer-associated fibroblast (CAF) cells; exhibits favourable in vivo properties such as metabolic stability in mouse hepatocytes and bioavailability in µM concentrations in NSG mice for >10 h (IP injection); shows cytotoxicity in multiple low-passage patient-derived pancreatic cancer cell lines with IC50 of 1-4 uM in monolayer proliferation-based assays, prolongs survival significantly in orthotopic murine model of pancreatic cancer. |